World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
19 – 22 April 2018
ICE Krakow Congress Centre
Krakow, Poland
Events
Consilient Health with be attending the following conferences:
BioTrinity
23 – 25 April 2018
Novotel London West
London, UK15th Congress of the European Society of Contraception and Reproductive Health
9 – 12 May 2018
HungExpo
Budapest, HungaryEuropean Calcified Tissue Society
26 – 29 May 2018
Valencia Conference Centre
Valencia, SpainBio International Convention
4 – 7 June 2018
Boston Convention & Exhibition Center
Boston, USA
Please contact us if you are interested in meeting.
News
Code No: UK/CH/0917/0013a
Date of Preparation: September 2017
Consilient Health signs long-term distribution agreement for elmiron® with bene-Arzneimittel GmbH
/in News /by Rebecca TaylorConsilient Health are pleased to announce the signing of a long-term, exclusive distribution agreement with bene-Arzneimittel GmbH, a Munich-based pharmaceutical company, to distribute elmiron® in the UK. elmiron® allows Consilient Health to expand in to the exciting urology segment and is in line with the company’s strategy of partnering with innovative companies to bring to […]
Consilient Health Limited Announces Board Changes
/in News /by Rebecca TaylorConsilient Health is pleased to announce the appointment of Mr John Dixon as Non-Executive Director of the Company. John joined the pharmaceutical industry in 1974 and, from 1982, remained with Boehringer Ingelheim. During that time John is well known for heading up the Global Respiratory Marketing function and for launching BI’s first ever blockbuster “Spiriva” […]
Consilient Health Recognised at Prestigious UK PM Society Awards
/in News /by Rebecca TaylorConsilient Health are pleased to announce that the UK/Ireland marketing team was awarded a bronze craft award for Targeted Secondary Care Communication, for a partner brand. There were eight strong finalists and to be selected for a bronze award by a judging group of peers, healthcare professionals and agencies is testament to the focus and […]
MYSIMBA▼® (naltrexone/bupropion) NICE ORAL APPEAL REJECTED
/in News /by Rebecca TaylorThe Oral Appeal to the National Institute for Health and Care Excellence for Mysimba, the oral, anti-obesity medicine has been rejected. Mysimba was licensed in the European Union in 2015. It is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with […]